Literature DB >> 8295258

Detection of the BCR/ABL fusion gene in chronic myeloid leukemia by RNA polymerase chain reaction.

X H Qian1, A D Yang, H B Fei, C C Wang.   

Abstract

The bcr/abl fusion gene in 20 patients with chronic myeloid leukemia (CML) was detected by RNA polymerase chain reaction, which used mRNA as the starting material to generate cDNA with reverse transcriptase followed by PCR amplification (RNA/PCR). Amplification of a sequence spanning the bcr/abl junction region was achieved by using peripheral blood cells as the source of mRNA from all 20 patients with CML, including 3 cases of Ph (-) CML, and cell line K562 was derived from patients with CML. No amplification was seen when mononuclear cells from 3 normal individuals, 2 patients with lymphoma and cell line HL-60 were used. The presence or absence of bcr exon 3 in the fusion mRNA was determined by the size of the amplified fragments. Of the 20 CML patients, 15 showed only the 165-bp amplified band (indicating retention of bcr exon 3), one showed only the 90-bp amplified band, and 4 showed both 165-bp and 90-bp bands. Both bands were seen more frequently in blast crisis than in remission and chronic phase.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8295258     DOI: 10.1007/BF02886502

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  9 in total

1.  Polymerase chain reaction for detection of residual leukaemia.

Authors:  G J Morgan; T Hughes; J W Janssen; J Gow; A P Guo; J M Goldman; L M Wiedemann; C R Bartram
Journal:  Lancet       Date:  1989-04-29       Impact factor: 79.321

2.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Authors:  E Shtivelman; B Lifshitz; R P Gale; E Canaani
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

3.  Molecular abnormalities of bcr and c-abl in chronic myelogenous leukemia associated with a long chronic phase.

Authors:  O Dreazen; M Berman; R P Gale
Journal:  Blood       Date:  1988-03       Impact factor: 22.113

4.  Exclusion of chromosomal mosaicism: tables of 90%, 95% and 99% confidence limits and comments on use.

Authors:  E B Hook
Journal:  Am J Hum Genet       Date:  1977-01       Impact factor: 11.025

5.  Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction.

Authors:  M S Lee; A LeMaistre; H M Kantarjian; M Talpaz; E J Freireich; J M Trujillo; S A Stass
Journal:  Blood       Date:  1989-06       Impact factor: 22.113

6.  CML patients in blast crisis have breakpoints localized to a specific region of the BCR.

Authors:  K Schaefer-Rego; H Dudek; D Popenoe; Z Arlin; J G Mears; A Bank; D Leibowitz
Journal:  Blood       Date:  1987-08       Impact factor: 22.113

7.  Structural organization of the bcr gene and its role in the Ph' translocation.

Authors:  N Heisterkamp; K Stam; J Groffen; A de Klein; G Grosveld
Journal:  Nature       Date:  1985 Jun 27-Jul 3       Impact factor: 49.962

8.  Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia.

Authors:  M S Roth; J H Antin; E L Bingham; D Ginsburg
Journal:  Blood       Date:  1989-08-01       Impact factor: 22.113

9.  Detection of the molecular abnormality in chronic myeloid leukemia by use of the polymerase chain reaction.

Authors:  A Dobrovic; K J Trainor; A A Morley
Journal:  Blood       Date:  1988-12       Impact factor: 22.113

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.